research centers


Search results: Found 14

Listing 1 - 10 of 14 << page
of 2
>>
Sort by

Article
Immunohistochemical Expression of Her2/Neu Receptor in Human Colorectal Carcinoma (A Clinicopathological Study)

Author: Kifah Hamdan AbdulGhafour
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2014 Volume: 13 Issue: 3 Pages: 424-429
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT:BACKGROUND: Colorectal adenocarcinoma is the most common type of gastrointestinal cancers in Iraq, and according to the Iraqi cancer registry (ICR) reports, the incidence of colorectal carcinoma was 2.99% of whole body malignancies (ICR 2010). In males, it’s the 5th common cancer while in females it’s the 4th most common cancer. Her2/neu is an important oncogene in breast cancer, but its prevalence and significance in colorectal carcinoma have been documented.OBJECTIVE:To determine the frequency and the pattern of Her2/neu expression in colorectal adenocarcinoma by immunohistochemical technique and to correlate this expression with different clinicopathological parameters.MATERIAL AND METHOD:Twenty five cases of colorectal adenocarcinoma were studied, these cases were diagnosed in private laboratories in Baghdad/Iraq from November 2011 to march 2013. Clinicopathological parameters such as age, gender, pathological diagnosis, including the tumor site, size, lymph nodes status, grade and stage of tumor were taken from patients file. Sections of 4 µm stained by H&E stain and immunohistochemical stained for Her2/neu.Using infiltrative ductal carcinoma of the breast as control positive, evaluation of Her2/neu expression by immunohistochemistry in all cases was performed.RESULTS: Fourteen (56%) of the cases were males, 11 (44%) case were females, with age distribution ranging from (24-89) years, with a mean age of 56.5 years. Tumor size ranges between 2.5-10 cm, with mean of 6.25 cm. Seven (28%) cases were localized in the cecum, 5 (20%) from each rectum, sigmoid and left colon, respectively and 3 (12%) involving more than one segment of the colon. Histologically the tumor grade ranges from moderately differentiated in 23 (92%) cases and poorly differentiated in 2 (8%) cases. Regarding pathological staging (TNM system), 5 (20%) were stage T2, 17 (68%) were stage T3 and 3 (12%) were T4. Lymph node involvement found in 10(40%) of the cases and distant metastasis was found in 2 (12%) cases. Her2/neu expression was present in 4(16%) cases of 25 colorectal adenocarcinoma; there was no correlation with age, sex, histopathological grade, location, lymph nodes status and tumor invasion. CONCLUSION: Concerning data exists about the prevalence of her2/new expression in colorectal adenocarcinoma, there was no significant correlation between her2/neu over expression and tumor size, grade, localization of the primary tumor, lymph nodes status and depth of invasion.


Article
Immunohistochemical expression of HER2/neu in colorectal carcinoma in Erbil city, Kurdistan Region

Authors: Lilav Adel Kamal --- Jalal Ali Jalal
Journal: Zanco Journal of Medical Sciences مجلة زانكو للعلوم الطبية ISSN: 19955588/19955596 Year: 2019 Volume: 23 Issue: 3 Pages: 421-428
Publisher: Hawler Medical Univeristy جامعة هولير الطبية

Loading...
Loading...
Abstract

Background and objective: Colorectal carcinoma is one of the commonest cancers and the second leading cause of cancer death in Europe and North America. Despite the improved surgeries and adjuvant therapies, the prognosis of colorectal cancer remains poor, and the survival rate is unsatisfactory. Overexpression of HER2 gene has been noticed in many human cancers, and it is associated with poor prognosis. This study aimed to detect the frequency of the HER2/neu immunoexpression in colorectal carcinoma and investigate its association with the clinicopathological parameters.Methods: A retrospective study was carried out in Rizgary teaching hospital and private laboratories in Erbil city for the period from January 2014 - December 2017. A total of 103 formalin fixed, paraffin embedded, archival tissue blocks of colectomy samples of colorectal carcinoma cases were collected. Immunostaining was done in a private laboratory (Vin Lab) in Dohuk city. Scoring of the HER2/neu immunostaining was managed according to published criteria for breast carcinoma.Results: Fifty-five cases (53.4%) were labeled as positive for HER2/neuimmunoexpression. While 48 (46.6%) of the cases were labeled as negative. HER2/neu status was significantly associated with the tumor grade (P = 0.02), while no significant association was found between HER2/neu expression and other clinicopathological parameters.Conclusion: HER2/neu immunoexpression was observed in 53.4% of the cases of colorectal carcinoma, and it was significantly associated with tumor grade.


Article
Expression of p53 and her2/neu in serous ovarian carcinoma with different grades of differentiation (Immunohistochemical Study)
التعبير المفرط لعامل النمو البشراويHer2/neu وعامل ((P53 في خبيث المبيض السطحي المصلي وعلاقتهما بدرجة التمايز النسيجي )دراسة مناعية نسيجية كيميائية)

Loading...
Loading...
Abstract

Objective: To assess the rate of immunohistochemical expression of Her2/neu and P53, and their coexistence in serous ovarian carcinoma in relation to the grade of differentiation as a prognostic parameter.Methods: Thirty cases of serous ovarian carcinomas and their corresponding paraffin blocks from 2008-2009 were submitted in this study in the Department of Pathology, College of Medicine, Kufa University. Ten biopsies of normal ovarian tissues were considered as control group. ABC method was used to determine the expression of Her2/neu and p53 in these cases. Statistically Chi square and regression tests were used by the help of SPSS version 10, using the P value significance at level < or 0.05 and 0.3 respectively. Results: p53 overexpression was detected in 13 cases (43.3%) while her2/neu was detected in 8 cases (26.6%) of serous ovarian cancer with 6.6% coexistence overexpression of both markers. None of the normal ovarian tissues revealed immunohistochemical expression for both p53 and Her2/neu, with significant level of expression between malignant and benign tissues (p< 0.001). p53 overexpression was reported more frequently in higher grades of differentiation with significant level of expression (p<0.05) this indicates that serous ovarian tumors with positive p53 expression are biologically bearing more aggressive behavior, while her2/neu expression show no positive correlation with the degree of differentiation, the relation about which a lot of debates are still present. Only 2 cases showed coexistent overexpression of both markers without significant difference with grade of tumor.Conclusion: p53 expression is significantly found in high grade ovarian serous carcinoma and considered to be a good prognostic parameters, while her2/neu overexpression has no significant difference among different grades of tumor. So coexistent overexpression of both markers could not be considered as significant prognostic parameter.

الأهداف: من اجل تقييم مغزى التعبير المفرط لعامل النمو البشراويHer2/neu وعامل P53 في سرطان المبيض في الإناث وعلاقته مع درجة التمايز.الطريقة: تم الحصول على 30 عينة مثبتة بالفورمالين ومطمورة بالبارافين لمرضى مصابين بسرطان المبيض السطحي المصلي. كما تم الحصول على 10 نماذج لنسيج المبيض الطبيعي حيث استخدمت كمجوعة قياسية. استخدمت طريقة ABC لتحديد التعبير المناعي النسيجي لعامليHer2/neu و P53. النتائج والمناقشات: أظهرت ألنتائج أن التعبير النسيجي المناعي لـHer2/neu كان موجبا في 8 حالات 26.6)%( والتعبير النسيجي المناعي لـP53 كان موجباً في 13 حالة 43.3)%( من أورام المبيض بينما لم نلاحظ أي تعبير نسيجي لـHer2/neu و P53 في نسيج المبيض الحميد(P<0.001). إن زيادة شدة إظهار p53 (score+3 و score+4) سجلت المستويات الأعلى وإنها ترتبط بعلاقة ايجابية معنوية مع درجة التمايز مشيرة إلى إن أورام المبيض الخبيثة موجبة p53 هي عدوانية حيويا وتتواجد أكثر تكرارا في درجة التمايز الثالثة من درجة التمايز الأولى والثانية. إن تردد إظهار /neu her2وشدته لا ترتبط بعلاقة ايجابية معنوية مع درجة التمايز مشيرة إلى إن أورام المبيض الخبيثة موجبة her2/neu هي لا تزال موضع جدل حول أهميتها كعامل قياسي لعواقب أورام المبيض الخبيثة. إن التعبير المناعي النسيجي المتزامن للعاملين لا يشكل علاقة ايجابية معنوية مع درجة التمايز.الاستنتاج: من النتائج أعلاه يمكن لنا أن نستنتج أن p53 يلعب دور مهم في تولد و نشأة خبيث المبيض السطحي ويسند الدليل عن دوره في تكاثر الورم ونموه ودرجة تمايزه و ربما يسهم فهم دوره في إعاقة تكوين الورم أو في حالات متابعة فعالية العلاج المضاد للسرطان أو تقدير العواقب في حين أظهرت هذه الدراسة عن عدم وجود علاقه ايجابيه بين ظهور her2/neu ودرجة تمايز الورم.


Article
Immunohistochemical Study of Estrogen, Progesterone Receptor and Her-2neu Oncogene with Her-2neu Biomarker Estimation by ELISA Technique in Primary Breast Cancer before Chemical Therapy
دراسة نسيجية مناعية لمستقبل هرمون الاستروجين والبروجستيرون والهير 2 نيو الورمي مع حساب العلامات البايولوجية للهير 2 نيو عن طريق تقنية اللايزا في مريضات مصابات لسرطان الثدي قبل العلاج الكيمياوي

Authors: Ali H. Al-Khafaji علي حسين الخفاجي --- Ayad M.A. Fadhil اياد محمد علي فاضل --- Mohammed A. Hameed محمد اياد حميد
Journal: Iraqi Journal of Science المجلة العراقية للعلوم ISSN: 00672904/23121637 Year: 2014 Volume: 55 Issue: 1 Pages: 132-144
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Breast cancer is one of the comments malignant tumors worldwide especially in Iraq; it is a leading cause of death in Iraqi women. Determination of estrogen and progesterone receptors status is helpful in selecting the patients most likely to receive benefit from endocrine therapy, and provide prognostic information on recurrence and survival since their expression is related to the degree of the tumor differentiation. From November 2012 to March 2013, 150 breast cancer patients at Al-Amal Hospital in Baghdad were attended to start treatment of disease for the first time. All patients included in this study did not receive chemotherapy. Patients were asked to bring their paraffin embedded tissue blocks to participate in estrogen, progesterone and Her-2/nue receptors estimation. Blood samples were also collected from the patients to estimate positive Her-2nue cases in serum. Age distribution in women with breast cancer showed that 44%of cases at age group (40 – 49) years. 23% of the patients had a positive family history (first and second degree). Histological types of breast carcinoma showed that 82%, 14% and 4% were ductal, lobular and mixed carcinoma respectively. The Makee classification showed that Grade I, II, and III were detected in 10%, 64% and 26% respectively. TNM staging revealed that 16% of the patients were recorded in stage I, 44% in stage II, 32% in stage III and 8% in stage IV. It was demonstrated that 72% and 70% of breast carcinomas were positive for ER and PR respectively; both markers correlated with age, family history, type, histological grade and stage of the disease. Her-2/neu showed 28% expression in Iraqi breast cancer cases. HER2/neu over-expression (>15 ng/ml) was observed in 36 out of 150 patients (24%) Her-2/neu serum level at ELISA diagnosis and in 42 out of 150 (28%) at immunohistochemistry method (IHC).There were significant (P <0.001) association between tissue HER-2/neu and serum HER-2 levels. Detection Her-2/neu in serum by ELISA technique could be used as a method for detection with high rate reached to 78% after mastectomy, also it considered as an excellent method for follow up.

يعد سرطان الثدي احد اكثر انواع السرطان شيوعا في العالم واحد اهم اسباب الوفاة بين نساء العراق ولقد كان لاكتشاف مستقبلات الهرمونات (استروجين و بروجستيرون) فضل كبير في اختيار المريضات للخضوع للعلاج الهرموني ولتوقع فترة العيش بعد العلاج وامكانية رجوع الورم مرة اخرى وذلك للعلاقة بين درجة الورم ونسبة تمثيل مستقبلات الهرمون على سطح الخلايا, يقوم البحث على اساس قياس نسبة ER, PR &HER2neu في النسيج ومصل الدم وملاحظة العلاقة بين مستوى المستقبلات والحالة الاكلينيكية في نساء عراقيات مصابات بسرطان الثدي قبل وبعد الخضوع للعلاج الكيميائي, تم بدأ الدراسة من تشرين الثاني 2012 الى اذار 2013 في مستشفى الامل وتم اختيار المشخصات حديثا بالاصابة بسرطان الثدي وقبل بدأ العلاج الكيميائي للمشاركة في الدراسة , تم اخذ النسيج المنطمر في البارافين وعينة من الدم من 150 مريضة لمعرفة نسبة الHER2neu الموجبة (اهم بارامتر في الدراسة) 44%من النساء المشمولات في الدراسة كن بين 40-49سنة, 23% لهن اقارب من الدرجة الاولى والثانية مصابات بالمرض, 82% كان من نوع سرطان القنوات,14% من نوع قصيبي و 4% من النوع المختلط, 64% من الدرجة الثانية,10% من الدرجة الاولى و16% من الدرجة الثالثة حسب تصنيف SBR, باستخدام تصنيف TNM 16% في المرحلة الاولى 44% في المرحلة الثانية.32% في المرحلة الثالثة و8% في المرحلة الرابعة وكلاهما علامات مرتبطة مع التقدم في العمر والتاريخ العائلي ونوع ودرجة النسيجية ومرحلة المرض. التحليل المناعي immunohistochemistry over expression) ( كشف عن 42(28%)حالة زيادة او افراط في التعبير للجين الورمي HER2neu وباستخدام تقنية الفحص المناعي المرتبط بالانزيم ELISA كانت نسبة فرط التعبير 22% بمتوسط يبلغ 17.9 نانوغرام/مل بمدى 12.8_29.9نانوغرام/مل P value<0.001, r=0.53. هناك فروقات معنوية (P <0.001) مرتبطة ما بين مستويات HER-2/neu اللنسيجية و HER-2 مصل الدم. الكشف عن مستقبلات ال Her-2neu في مصل الدم بواسطة تقنية ELISA يمكن أن تستخدم كوسيلة للكشف مع نسبة عالية وصلت إلى 78٪ بعد عملية استئصال الثدي، كما أنه تعتبرها وسيلة ممتازة لمتابعة العلاج(follow up). تعد تقنية التحليل المناعي اختبار سهل نسبيا ويمكن استخدامه لمراقبة فعالية انسجة الثدي.

Keywords

Breast Cancer --- ER --- PR --- Her2/neu


Article
Immunohistochemical expression of P16 and HER2/neu in normal oral mucosa, oral epithelial dysplasia, and oral squamous cell carcinoma

Authors: Suha ali Ahmed سهى علي احمد --- Ahlam Hameed Majeed احلام حميد مجيد
Journal: Journal of baghdad college of dentistry مجلة كلية طب الاسنان بغداد ISSN: 16800087 Year: 2014 Volume: 26 Issue: 2 Pages: 94-98
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Oncogenesis in the oral cavity is widely believed to result from cumulative genetic alterations thatcause a transformation of the mucosa from normal to dysplastic to invasive carcinoma. The p16 gene produces p16protein, which in turn inhibits phosphorylation of retinoblastoma (Rb), p16 play a significant role in earlycarcinogenesis. A number of epidermal growth factor receptor (EGFR) family, HER2/neu, has received muchattention because of its therapeutic implications. The aims of the study were to evaluate and compare theimmunohistochemical expression of the cell cycle protein P16 INK4a and c-erbB2 (HER2/neu) in NOM, OED, andOSCC. Correlate both marker expression with each other as well as with various clinicopathological findings.Materials and methods: Sixty two formalin-fixed, paraffin embedded tissue blocks (20 cases of normal oral mucosa,17 cases of oral epithelial dysplasia, and 25 cases of oral squamous cell carcinoma) were included in this study, animmunohistochemical staining was performed using anti p16 monoclonal antibody, and anti HER2/neu polyclonalantibody.Results: Positive IHC expression of p16 was found in 18 cases (90%) of NOM, 16 cases (94.1%) of OED and in 20 cases(80%) of OSCC. Positive IHC expression of HER2/neu was almost undetectable in NOM, while it was found in 9 cases(52.9%) of OED, and in 15 cases (60%) of OSCC.The correlation between the expression of both markers werestatistically highly significant in NOM, significant in OED, and non significant in OSCC.Conclusions: This study signify the important role of p16 and HER2/neu in oral carcinogenesis and in the evolution ofthe mucosa from normal to dysplastic to invasive carcinoma

الخلفیھ: عملیة التسرطن في التجویف الفمي غالبا ما تحدث نتیجة تراكم التغییرات الجینیھ التي تحول الغشاء المخاطي الفموي و بخطوات عدیده من الطبیعي الى الحثل النمويیلعب دورا مھما في عملیة p وكذلك فان بروتین 16 ,Rb الذي في المقابل یمنع فسفرة بروتین P فھو ینتج بروتین 16 p الطلائي ثم النسیج السرطاني المتغلغل.المورث الجیني 16والذي حظي اھتماما كبیرا بسبب تطبیقاتھ العلاجیھ. ( EGFR) فھو أحد افراد عائلة مستقبلات عامل نمو خلایا الأدمھ HER2/neu التسرطن المبكر. أمافي النسیج المخاطي الفموي الطبیعي ,و الحثل النموي الطلائي الفموي HER2/neu ومحفز p16 INK4a اھداف الدراسھ: تقییم التعبیر المناعي النسیجي الكیمیائي لبروتینمع بعضھما وكذلك علاقتھما مع المقاییس السریریھ والمرضیھ HER2/neu و p ,وسرطان الفم الحرشفي . وكذلك اكتشاف علاقة المورثات الجینیھ 16المواد وطرق العمل :تشمل الدراسھ اثنان وستون حالھ مختاره من قوالب شمع البارافین, تضمنت 20 حالھ من الغشاء الفموي الطبیعي و 17 حالھ من الحثل النموي الطلائي الفموي.HER2/neu وp و 25 حالھ من سرطان الفم الحرشفي.و اجراء الفحوصات المناعیھ الكیمیائیھ النسیجیھ باستخدام المؤشرات 16كان قد تبین في 18 حالھ ( 90 %) من الغشاء الفموي الطبیعي و الذي اظھر تعبیر p النتائج : اظھرت الدراسھ الحالیھ ان التعبیر الایجابي المناعي النسیجي الكیمیائي لبروتین 16في 20 حالھ ( 80 %) من سرطان p ایجابي ضعیف, كما وظھر التعبیر الایجابي في 16 حالھ ( 94.1 %) من الحثل النموي الطلائي الفموي ,. بینما كان التعبیر الایجابي لبروتین 16قد تبین HER لم یتم الكشف عنھھ في الغشاء الفموي الطبیعي, بینما في الحثل النموي الطلائي الفموي كان الظھور الایجابي ل محفز 2 HER الفم الحرشفي .التعبیر الایجابي لمحفز 2p كان قد وجد في 15 حالھ ( 60 %) من سرطان الفم الحرشفي. العلاقھ الاحصائیھ بین المؤشرین 16 HER في تسع حالات( 52.9 %), بینما التعبیر الایجابي لمحفز 2كانت معنویھ للغایھ في الغشاء الفموي الطبیعي , وكذلك كانت العلاقھ معنویھ في الحثل النموي الطلائي الفموي , في حین انھ لم تكن ھناك علاقھ معنویھ بین المؤشرین HER2/neu وفي سرطان الفم الحرشفي.في عملیة التسرطن وكذلك في تطور الغشاء المخاطي الفموي من الطبیعي الى الحثل النموي HER2/neu ومحفز p الاستنتاجات :كشفت ھذه الدراسھ على الدور المھم لبروتین 16ثم الى سرطان الفم الحرشفي.

Keywords

NOM --- OED --- OSCC --- P16 --- HER2/neu


Article
Mouse monoclonal antibodies and immunohistochemical technique for determination of sex steroid receptors and human epidermal growth factor receptor in breast cancer

Journal: Muthanna Medical Journal مجلة المثنى الطبية ISSN: 2226146x Year: 2015 Volume: 2 Issue: 1 Pages: 15-22
Publisher: Al-Muthanna University جامعة المثنى

Loading...
Loading...
Abstract

Breast cancer is one of the most common malignancies in women. The current study was conducted with the objective of assessing estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2/neu) reactivity patterns of breast cancers and to evaluate their association with clinicopathological features. Immunohistochemical (IHC) procedure was used to detect the expression of ER, PR and HER2/neu in postoperative paraffin blocks of breast tumors and statistically analyzed their correlations with clinicopathological characteristics. Most of the patients (66.0%) were ≤50 years at diagnosis. The left breast was more commonly involved (57%), tumor size ranged from 0.5 - 13.0 cm. The staining of Her2/neu was mainly localized in the membrane, whereas ER, PR, were localized in the nucleus. ER positivity was observed in 70% grade I, 48.2% grade II and 3.5% grade III carcinomas (P<0.05). Similarly PR positivity was observed in 70% grade I, 36.14% grade II and 1.75% grade III carcinomas (P<0.05). HER2/neu was positive in 1 (10%) case of grade I carcinoma, 31 (37.35%) cases of the grade II carcinoma and 24 (42.11%) cases of grade III carcinoma. In the HER-2/neu positive tumors, ER and PR expression in high grade tumors was significantly decreased compared with intermediate grade tumors (ER 5.6% vs 10.5; PR 0% vs 5.3%). Among the ER, PR and HER2/neu statuses, a significant correlation was observed between ER expression and PR status (P<0.05), whereas the expression of ER and PR exhibited a negative correlation with HER2 status (P<0.05). We also demonstrated a significant correlation between the HER2/neu subtypes with poor histological grade (P<0.05). In conclusion, there is a definite correlation between IHC indices and clinicopathological characteristics in breast carcinomas.


Article
Her 2/Neu Overexpression in Gastric Cancer

Author: Nadwa Subhi Al-Azow
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2014 Volume: 13 Issue: 2 Pages: 268-272
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT: BACKGROUND :Overexpression of Human epidermal growth factor receptor 2(Her2/neu)Protein has been observed in many human cancers including gastric cancer . Gastric cancer remains the most common cause of cancer –related death worldwide. Her2/neu overexpressionin gastric cancer associated with poor prognosis and shorter survival rate , the assessment of this protein for selection of eligible patients for treatment with trastzumab in addition to conventional chemo therapy.OBJECTIVE: To evaluate the Her2/neu over expression in gastric cancer by immunohistochemicalTechnique and to find the correlation between the protein exopression and clinicopathological Parameters as age ,sex, histological types and grade of the tumor.MATERIALS AND METHODS : This is a pro-& retrospective study conducted at the pathology department of Al-Jamhuri Teaching hospital and some private laboratories . A total of 30 cases of gastric cancer were collected and diagnosed in the period spanning from April 2010 to April 2012, .An immunohistochemical technique was used for the assessment of Her2 against age,sex, histological types and grade of tumor RESULTS : The mean age of the patients was 54.5 years ranging from 30 to 87 years, Her2/neu overexpression was shown in 30% of the cases , in this study there is no relation between Her2 positivity and age or sex, , it was associated with histological types p-value = 0.04,where as 42.6 % of the intestinal type show immunoreactivity and 11.1% of diffuse type,while two cases of mixed types were shown no reactivity(0.0% ). Her2 positivity was associated with moderate differentiated tumor (50%) more than poorly differentiated (20%) but not reaching the statistical significance.CONCLUSION: Her2/neu positivity was found in 30% of gastric cancer , there is no relation between the age or sex of the patient & Her2 positivity while intestinal type and moderately differentiated tumor were associated with high percentage of Her2 positivity.


Article
7.DEFICIENCY OF SERUM 25-HYDROXYVITAMIN D IN PATIENTS WITH BREAST CANCER IN IRAQ

Author: Taha H.T. Al-Saigh طه الصائغ
Journal: IRAQI JOURNAL OF MEDICAL SCIENCES المجلة العراقية للعلوم الطبية ISSN: P16816579,E22244719 Year: 2018 Volume: 16 Issue: 4 Pages: 400-404
Publisher: Al-Nahrain University جامعة النهرين

Loading...
Loading...
Abstract

Background: Many studies defined the association between vitamin D and breast cancer. The relation between human epidermal growth factor receptor 2 (Her2/nue), estrogen or progesterone receptors and vitamin D in breast cancer patients was not clear, since few studies was conducted.Objective: To find out the association of deficiency of vitamin D and breast cancer. The effect of Her2/neu, estrogen, and progesterone receptors on vitamin D in the breast cancer patients was also studied.Methods:Forty patients with benign breast lump as a control group and 40 patients with breast cancer early diagnosed were included in the study. Blood samples (5 mL) were taken from the control and patient groups and analyzed for serum 25-hydroxyvitamin D by using chemiluminescent immunoassay technology. Serum cancer antigen (CA15-3) was measured by using monoclonal antibodies against CA15-3. HER2/neu, estrogen and progesterone receptors were determined in breast cancer patients by immunochemical method.Results: Serum vitamin D in the breast cancer patients before surgery was significantly lower (p ≤ 0.05) than that in the control group. Preoperatively, serum CA15-3 in Her2/neu positive patients was significantly (p ≤ 0.05) higher than that in Her2/neu negative patients. Postoperatively, serum CA15-3 in Her2/neu positive patients was not significantly different from that in Her2/neu negative patients. Serum vitamin D, after surgery, in Her2/neu positive patients was not significantly different from that in Her2/neu negative patients. Serum vitamin D was not significantly different in estrogen and progesterone positive patients from that in estrogen and progesterone negative patients, respectively.Conclusion: Severe deficiency of vitamin D was noticed in breast cancer patients in Iraq, and mild deficiency in benign subjects. Serum CA15-3 was higher in positive Her2/neu than negative patients before operation. Her2/neu, estrogen and progesterone positive receptors have no effect on serum vitamin D level in breast cancer patients.Keywords: Vitamin D, breast cancer, CA15-3, Her2/neuCitation: Al-Saigh THT. Deficiency of serum 25-hydroxyvitamin D in patients with breast cancer in Iraq. Iraqi JMS. 2018; 16(4): 400-404. doi: 10.22578/IJMS.16.4.7

Keywords

Vitamin D --- breast cancer --- CA15-3 --- Her2/neu


Article
Association of Serum Leptin and C-Reactive Protein in Women with Breast Cancer
علاقة مصل دم اللبتين وبروتين التفاعل نوعC في النساء المصابات بسرطان الثدي

Authors: Faris A Ahmed --- Zainab M Al-Shammaa
Journal: Al-Mustansiriyah Journal for Pharmaceutical Sciences مجلة المستنصرية للعلوم الصيدلانية ISSN: 18150993 Year: 2018 Volume: 18 Issue: 1 Pages: 128-134
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

This study was conducted to evaluate the association of serum leptin and hs C-reactive protein with breast cancer. Two groups were included in the study. The first group included 45 newly diagnosed women with breast cancer. The second group included 42 women with benign breast lump as a control group. Blood samples (5 mL) were taken from the patient and the control groups and analyzed for serum leptin and hs C-reactive protein. Serum CA15-3 was also measured in breast cancer patients. The epidermal growth factor receptor 2 (HER2/neu), estrogen and progesterone receptors were determined in breast cancer patients by using immune-chemical method. Serum leptin was significantly higher (p ≤ 0.05) in breast cancer patients than that in the control group; however, no significant difference was noticed between the two groups for serum hs C-reactive protein. No significant difference was noticed between HER2/neu positive or negative in breast cancer patients for serum leptin or hs C-reactive protein. However, serum CA15-3 in HER2/neu positive patients was significantly higher (p ≤ 0.05) than that in HER2/neu negative patients. No significant difference was noticed between positive and negative estrogen breast cancer patients for serum leptin, hs C-reactive protein or CA15-3. In addition, no significant difference was noticed between positive and negative progesterone for serum leptin, hs C-reactive protein or CA15-3. A strong significant positive correlation was noticed between serum leptin and BMI in the control group; however, no significant correlation was noticed between serum leptin and BMI in the breast cancer patients. In conclusion, serum leptin may be used as a prognostic factor for breast cancer. Serum C-reactive protein in HER2/neu positive breast cancer patients is higher than in HER2/neu negative patients.

أجريت هذه الدراسة لتقييم علاقة مصل دم اللبتين والبروتين التفاعل عالي الحسلسية نوع Cبسرطان الثدي. شملت الدراسة على مجموعتين، احتوت المجموعة الاولى على 45 امرأة مصابة ومشخصة حديثا بسرطان الثدي. وشملت المجموعة الثانية على 42 امرأة مشخصة بكتلة حميدة في الثدي كمجموعة سيطرة. اخذت عينات الدم ( 5 مل) من المريضات ومن مجموعة السيطرة وتم قياس مصل دم اللبتين وبروتين التفاعل عالي الحساسية نوع C. وكذلك تم قياس مصل دم CA15-3 في المريضات المصابات بسرطان الثدي. وتم تحديد المستقبل الثاني لعامل نمو البشرة البشري (HER2/neu) ومستقبلات الاستروجين والبروجستيرون في المريضات المصابات بسرطان الثدي باستعمال طرق كميائية مناعية. وكان مصل دم اللبتين في المريضات المصابات بسرطان الثدي اعلى معنويا (p ≤ 0.05) منه في مجموعة السيطرة. من ناحية اخرى لم يكن هناك فرق معنوي بين المجموعتين لمصل دم بروتين التفاعل عالي الحساسية نوعC . ولم يكن هناك فرق هناك فرق معنوي بين مصل دم اللبتين وبروتين التفاعل عالي الحساسية بين مريضات HER2/neu الموجب والسالب. من ناحية اخرى كان مصل دم CA15-3 في مريضات HER2/neu الموجب اعلى منه (p ≤ 0.05) معنويا في المرضى السالب. ولم يكن هناك فرق معنوي لمصل دم كل من اللبتين وبروتين التفاعل عالي الحساسية و CA15-3 بين مريضات الاستروجين الموجب والسالب. كذلك لم يكن هناك فرق معنوي لمصل دم كل من اللبتين وبروتين التفاعل عالي الحساسية وCA15-3 بين مريضات البروجستيرون الموجب والسالب. وكان هناك علاقة طردية قوية بين مصل دم اللبتين ومؤشركتلة الجسم في مجموعة السيطرة. من ناحية اخرى لم يكن هناك علاقة معنوية بين مصل دم اللبتين ومؤشر كتلة الجسم في المريضات المصابات بسرطان الثدي. وكان الاستنتاج ان مصل دم اللبتين من الممكن ان يستعمل كعامل تشخيصي لمرض سرطان الثدي. ان مصل دم بروتين التفاعل عالي الحساسية في مرضى سرطان الثدي نوع HER2/neu الموجب اعلى منه في المرضى السالب.


Article
Breast Cancer in Mosul: A Survival Analysis
سرطان الثدي في الموصل: تحليل البقاء على قيد الحياة

Loading...
Loading...
Abstract

Breast cancer is the most common cancer in women, and the major cause of death. This study was conducted in order to make a descriptive study and survival analysis for breast cancer patients in Mosul. Two hundred forty-six early diagnosed women with breast cancer out of 290 patients were included during the period from March 2007 to February 2012. The average follows up was 36.months (range: 11-67 months). The patients were undergone modified radical removal of the breast, chemotherapy and deep radiation. Patients with estrogen positive were given tamoxifen for five years. Patients with Her2/neu positive were given trastuzumab with docytaxil for one year. Only 25 patients (10.2%) died during the study. The highest incidence of breast cancer (35.8%) was between the ages 51 ≥ 60 years. The presentation of cancer was high (90.1%) in the lumber. Tumor in the right side (66.35%) was significantly higher than the left side. Metastasis was high (25%) and most of them in the liver (19.1%). The percentage of patients with positive estrogen, progesterone, and Her2/neu receptors were not different from negative receptors. Cox regression analysis showed that metastasis had significant effect on death (hazard ratio=2.917). Age 31 ≥ 40 years was the least affected age (hazard ratio=0.034). In conclusion, survival rate of breast cancer patients in Mosul is high due to good management. The early detection of cancer is the best way for survival of the patients, by developing the educational programs.

يعتبر سرطان الثدي الاكثر شيوعيا في النساء وهو السبب الرئيسي للوفاة. اجريت دراسة وصفية وتحليل البقاء على الحياة للمريضات بسرطان الثدي في الموصل. وشملت الدراسة على 246 من النساء المصابات بسرطان الثدي من اصل 290 مريضة لللفترة من اذار 2007 الى شباط 2012. وكان معدل متابعة المرضى 36 شهرا (ما بين 11-67 شهرا). وكان قد اجريت عملية رفع الثدي للمريضات، والعلاج الكيميائي والاشعائي.. واعطيت المريضات حاملة موجب الاستروجين عقارتاموكسيفين ولمدة خمسة سنوات. اما المريضات حاملة Her2/neu الموجب فقد اعطيت عقار trastuzumab مع عقار docytaxil لمدة سنة. ومات 25 مريضة (10.2%) خلال فترة الدراسة. وكانت اعلى نسبة بسرطان الثدي (35.8%) بين عمر 51 ≥ 60 سنة. وكان الصدر اعلى مكان للسرطان. وكان السرطان في الجهة اليمنى (66.35%) اعلى معنويا من الجهة اليسرى. وكان نسبة انتشار السرطان عالية (25%) ومعظمه في الكبد (19.1%). وكانت نسبة المريضات حاملة موجب المستقبلات الاستروجين والبوجستيرون و Her2/neu لا تختلف معنويا عن المريضات سالبة المستقبلات. وبين تحليل انحدار كوكس ان انتشار المرض له تاثير معنوي على نسبة الموتى (نسبة الخطر = 2.917). وكان العمر بين 31 ≥ 40 سنة هو العمر الاقل تأثرا بالسرطان. وكان الاستنتاج ان نسبة البقاء على الحياة لمريضات سرطان الثدي عالية في الموصل للعناية الجيدة. ان الكشف المبكر على سرطان الثدي هو احسن طريقة للبقاء على الحياة، ويكون من خلال البرامج التثقيفية.

Listing 1 - 10 of 14 << page
of 2
>>
Sort by
Narrow your search

Resource type

article (14)


Language

English (14)


Year
From To Submit

2020 (1)

2019 (1)

2018 (3)

2016 (1)

2015 (3)

More...